3,262 results on '"linagliptin"'
Search Results
2. Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
3. A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)
4. A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
5. Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
6. Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
7. The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers
8. Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin (AJU‐A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study.
9. Linagliptin's impact on lymphatic barrier and lymphangiogenesis in oral cancer with high glucose.
10. Electroanalytical sensing of antidiabetic drug linagliptin by using square-wave voltammetry on the boron-doped diamond electrode.
11. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series.
12. DIA_CENTRAL:T2D Treatment Pattern in Central Europe
13. Efficacy and Safety of Empagliflozin in NODAT
14. Comparison of Type 2 Diabetes Pharmacotherapy Regimens (ON TARGET DM)
15. Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus (EmLinaRenal)
16. Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial.
17. A Comparison of Renal Effects between Empagliflozin and Linagliptin in Diabetic Patients with Chronic Kidney Disease: A Randomized Clinical Trial
18. Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
19. A Comparison of Renal Effects between Empagliflozin and Linagliptin in Diabetic Patients with Chronic Kidney Disease: A Randomized Clinical Trial.
20. Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial
21. Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases.
22. Anticancer and Antioxidant Effects of Sitagliptin and Linagliptin against Lung Cancer Cell Lines (an In vitro Study).
23. Synergistic Antitumor and Apoptotic Activity of Sitagliptin or Linagliptin Plus Cisplatin Against A549 Lung Cancer Cells (An Invitro Study).
24. Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations
25. Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)
26. Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation – A Case Study of the DINAMO Trial
27. Treating hyperglycaemia in a patient with maternally inherited diabetes and deafness with an inhibitor of dipeptidyl peptidase-4: a case report and two-year follow-up
28. Green quantitative methods for linagliptin and empagliflozin in dosage forms
29. Replication of the CARMELINA Diabetes Trial in Healthcare Claims
30. Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects
31. Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus (DÁLIA)
32. A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition
33. A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers
34. Semaglutide and Patients Receiving Hemodialysis: Case Reports of Unexpected Benefits for Hyperphosphatemia and Hyperkalemia.
35. Linagliptin in combination with insulin suppresses apoptotic unfolded protein response in ovaries exposed to type 1 diabetes.
36. Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats.
37. Identification and Structural Characterization of Degradation Products of Linagliptin by Mass Spectrometry Techniques.
38. Mechanism of Linagliptin on Stromal Cell-Derived Factor 1 and Vascular Endothelial Growth Factor Protein after Molar Pulp Revascularization in Rats.
39. Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics.
40. Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: Recent advances in synergistic strategies for maximizing control of high-risk type II diabetes.
41. Linagliptin, a DPP‐4 inhibitor, activates AMPK/FOXO3a and suppresses NFκB to mitigate the debilitating effects of diethylnitrosamine exposure in rat liver: Novel mechanistic insights.
42. Pylorus ligation-induced hyperacidity: synergistic prophylactic effects of linagliptin and L-arginine via up-regulation of EP4 receptor subtype and improvement of vascular endothelial damage.
43. The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (1971)
44. Comparison of the efficacy of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients with normal body mass index and poor metformin monotherapy
45. Linagliptin's Effect on CD34+ Stem Cells
46. HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
47. Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
48. Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin
49. A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin.
50. Simultaneous estimation of dapagliflozin and linagliptin using reverse phase-HPLC with photo diode array (PDA).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.